Eli Lilly has introduced successful weight loss drugs, Tirzepatide and Mounjaro, generating over $1 billion in revenue. Their dual GIP/GLP-1 receptor agonist drugs regulate blood sugar levels and appetite.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing